Anzeige
Mehr »
Login
Donnerstag, 18.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Kurze Gold-Preis-Konsolidierung zum Einstieg in diese Aktie nutzen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EWWP | ISIN: US34960Q3074 | Ticker-Symbol: CNB1
NASDAQ
18.04.24
15:30 Uhr
1,790 US-Dollar
-0,025
-1,38 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
FORTRESS BIOTECH INC Chart 1 Jahr
5-Tage-Chart
FORTRESS BIOTECH INC 5-Tage-Chart

Aktuelle News zur FORTRESS BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
29.03.Fortress Biotech Inc reports results for the quarter ended in December - Earnings Summary3
28.03.Fortress Biotech GAAP EPS of -$8.47 beats by $0.64, revenue of $84.51M beats by $4.83M5
28.03.Fortress Biotech, Inc.: Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights2.004Record consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs and BLAs in the next 18 months FDA accepted New Drug Application filing...
► Artikel lesen
28.03.Fortress Biotech, Inc. - 8-K, Current Report-
15.03.Fortress Biotech shares upgraded with $10 price target5
12.03.Fortress Biotech, Inc.: Fortress Biotech to Participate in 36th Annual ROTH Conference1
04.03.Fortress Biotech, Inc.: Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease117Encouraging preclinical studies demonstrate potential to combine AAV-ATP7A gene therapy with CUTX-101, which could be the first FDA-approved treatment for Menkes disease Cyprium Therapeutics, a majority-owned...
► Artikel lesen
13.02.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.02.2024 - 34.092The following instruments on Boerse Frankfurt do have their last trading day on 13.02.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.02.2024ISIN NameUS00941Q2030 AIRNET...
► Artikel lesen
13.02.Fortress Biotech, Inc. 9.375% CUM RED PER PREF SER A USD25.00 goes ex dividend tomorrow5
26.01.Fortress Biotech, Inc. - 8-K, Current Report6
10.01.Fortress Biotech 9.375% CUM PFD A goes ex-dividend tomorrow11
03.01.Fortress Biotech, Inc. - 8-K, Current Report4
03.01.Fortress Biotech, Inc.: Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules7
29.12.23Nasdaq Down Over 100 Points; Fortress Biotech Shares Plummet6
29.12.23Why Fortress Biotech Shares Are Tumbling Today5
29.12.23Fortress Biotech Announces Pricing Of Registered Direct Offering4
29.12.23Fortress Biotech drops on plans to issue 3.3M shares1
29.12.23Fortress Biotech, Inc.: Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules5
07.12.23Organovo, Fortress Biotech among healthcare movers21
06.12.23Fortress Biotech, Inc.: Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lif211Cyprium received $4.5 million payment upon closing and remains eligible to receive royalties and up to $129 million in aggregate development and sales milestones Cyprium will retain 100% ownership...
► Artikel lesen
Seite:  Weiter >>
41 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1